News FTC doubles down on PBM criticism in new report A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
News PBM reform looms in end-of-year US legislation package Legislation that would introduce big changes for pharmacy benefit managers (PBMs) is inching closer to realisation in the US Congress.
News ICER identifies new crop of 'unsupported' drug price rises Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
Market Access Part Two: Navigating the complexities of global market acces... The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.
News BMS files legal challenge to HHS' 340B rebate decision Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.